The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

The stock price decline extends the sell-off, with Novo Nordisk down over 24% already in 2025 and over 39% in the last six months ... will take place this year, with the new prices set to ...

The Centers for Medicare & Medicaid Services (CMS) said Friday that it had selected another 15 drugs for its second round of ...

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...

The White House on Friday said Novo Nordisk's weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a round of price negotiations with Medicare. The companies do not have to ...

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock to "buy" from "neutral," calling the recent sell-off of the stock "overdone.

Over the last eight weeks, the big pharma stock has pulled ... Usually, the higher prices due to tariffs are passed along to consumers. Novo Nordisk's type 2 diabetes drug, Ozempic, is the main ...

Health care, ride sharing, and the emerging world of YouTube entertainers are among industries leading investors have picked ...

Novo Nordisk shares rose Wednesday on the company's home market in Denmark and in the U.S. after UBS analysts upgraded the stock ... Ozempic obesity drugmaker to a "buy," but lowered their price ...

The Centers for Medicare and Medicaid Services (CMS) listed Ozempic ... last year after its diabetes medication NovoLog was selected. The company said it “remains opposed to government price ...